It was with great pleasure that I assumed the role of Editor-in-Chief (EiC) of GaBI Journal in January of this year. Taking over the helm from Professor Philip D Walson is a considerable challenge; Phil’s excellent, thorough example will be very diffi cult to follow. My experience is restricted largely to biosimilars with which I have been involved since their concept and I will be relying on able colleagues for their expertise with generics! I
hope to be able to carry out the important job of EiC effectively and efficiently.